Revance Therapeutics Inc. (NASDAQ:RVNC) dropped 1.5% during trading on Thursday . The stock traded as low as $13.10 and last traded at $13.46, with a volume of 114,184 shares trading hands. The stock had previously closed at $13.66.

RVNC has been the subject of several research reports. Guggenheim reissued a “buy” rating and issued a $55.00 target price on shares of Revance Therapeutics in a research note on Monday, April 11th. SunTrust Banks Inc. assumed coverage on Revance Therapeutics in a research note on Wednesday, March 23rd. They issued a “buy” rating and a $46.00 target price for the company. Brean Capital restated a “buy” rating on shares of Revance Therapeutics in a research report on Tuesday, May 10th. Zacks Investment Research upgraded Revance Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research report on Wednesday. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $35.00 price target (down from $54.00) on shares of Revance Therapeutics in a research report on Tuesday, June 14th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $39.60.

The firm’s market cap is $395.11 million. The firm has a 50-day moving average of $15.45 and a 200-day moving average of $18.93.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.12. During the same quarter last year, the company earned ($0.65) EPS. Equities research analysts predict that Revance Therapeutics Inc. will post ($3.53) EPS for the current year.

Other hedge funds and institutional investors recently made changes to their positions in the company. Jennison Associates increased its position in shares of Revance Therapeutics by 0.8% in the third quarter. Jennison Associates now owns 78,156 shares of the biopharmaceutical company’s stock valued at $2,326,000 after buying an additional 603 shares during the period. Russell Frank Co bought a new position in shares of Revance Therapeutics during the fourth quarter valued at about $1,384,000. California State Teachers Retirement System increased its position in shares of Revance Therapeutics by 19.3% in the fourth quarter. California State Teachers Retirement System now owns 33,966 shares of the biopharmaceutical company’s stock valued at $1,160,000 after buying an additional 5,492 shares during the period. Finally, Oxford Asset Management bought a new position in shares of Revance Therapeutics during the fourth quarter valued at about $1,993,000.

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.